Interestingly, when the efficacy analysis was performed stratifying patients according to the PD-L1 expression status on infiltrating immune cells (ICs) in the tumour microenvironment, our analyses did not find any significant difference either in ORR, DoR, PFS or OS regardless of the IC group in patients treated with either atezolizumab or chemotherapy (Table 2). Here, CD274 is linked to neoplasm.